Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

DiabetologiaJun 8, 2026
Genetics of MASLD: a diabetes perspective

Clinical Context

We think this has broad domain relevance to RANO 2.0 for Gliomas.

DiabetologiaJun 6, 2026
Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

Clinical Context

We think this has broad domain relevance to RANO 2.0 for Gliomas.

WHO NewsMay 31, 2026
Joint statement by the Government of the Democratic Republic of the Congo and WHO concerning the outbreak of Ebola disease caused by the Bundibugyo virus

Clinical Context

We think this has broad domain relevance to RANO 2.0 for Gliomas.

RANO 2.0

RANO 2.0Glioma Response Framework

Radiographic Category

Clinical pearl

RANO 2.0 unifies the criteria for high-grade and low-grade gliomas. It emphasizes that Clinical Deterioration attributable to the tumor is sufficient to define PD, even if scans are stable.

Response Outlook

SD

Clinical Strategy

Stable Disease. Neither sufficient shrinkage to qualify for PR/MR nor sufficient increase to qualify for PD.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Used for all adult patients with diffuse gliomas (e.g., Glioblastoma, Astrocytoma, Oligodendroglioma) enrolled in clinical trials or routine care.
Standardizes the MRI interpretation of T1 gadolinium-enhancing and T2/FLAIR non-enhancing disease.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the CNS-IPI or the NSCLC GPA to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

CNS-IPI
NSCLC GPA
IPSS-M
Lung-RADS v2022
TNM 9th Ed
IGCCCG Risk
Z0011 Eligibility
IMWG Myeloma Frailty
HCT-CI
RCB
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.